Last reviewed · How we verify
NCT07044349
Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 trial testing Utidelone capsule 75mg/m2/d QD in Ovarian Cancer in 72 participants. Not yet recruiting.
1 March 2027
Quick facts
| Lead sponsor | Beijing Biostar Pharmaceuticals Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 72 |
| Start date | 1 September 2025 |
| Primary completion | 1 March 2027 |
| Estimated completion | 1 March 2027 |
Drugs / interventions tested
- Utidelone capsule 75mg/m2/d QD — full drug profile →
- Utidelone capsule 40mg/m2/d BID — full drug profile →
- Utidelone capsule 50mg/m2/d BID — full drug profile →
- Utidelone capsule 35mg/m2/d BID — full drug profile →
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
- Primary Peritoneal Cancer — all drugs for Primary Peritoneal Cancer →
Sponsor
Beijing Biostar Pharmaceuticals Co., Ltd. — full company profile →
Who can join
18 and older, female only, with Ovarian Cancer or Fallopian Tube Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Dose-limiting toxicity (DLT) and the maximum tolerated dose of the BID administration regimen
Time frame: Until 21 days after the first dose of treatment -
The incidence of adverse events (AE)/serious adverse events (SAE)
Time frame: Until 28 days after the last dose of treatment
Sponsor's own description
This is an open, multicenter, phase II clinical study enrolling patients with platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to evaluate the safety and efficacy of Utidelone Capsules. Approximately 72 patients will be included in this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07044349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Beijing Biostar Pharmaceuticals Co., Ltd. trials
Trials by the same sponsor.
- NCT06841679 — Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients Wi · Phase 2, PHASE3 · recruiting
- NCT06730581 — Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors · Phase 2 · not yet recruiting
- NCT06683703 — Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases · Phase 2 · not yet recruiting
- NCT05700084 — Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT05673629 — Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With H · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07044349 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Biostar Pharmaceuticals Co., Ltd.
- Last refreshed: 23 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07044349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing